secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2026-05-11T20:16:20+00:00
Accession:  0001104659-26-058666
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q1 LOQTORZI rev $11.8M (+61% YoY); net loss $36.9M; pipeline readouts mid-2026
--------------------------------------------------------------------------------

- LOQTORZI net revenue $11.8M in Q1 2026, up 61% YoY from $7.3M but down 5% from Q4 2025 $12.4M due to weather and seasonality.
- GAAP net loss from continuing ops $36.9M ($(0.27) diluted EPS) vs $47.4M ($(0.41)) in Q1 2025; non-GAAP net loss $33.9M ($(0.25)).
- Cash, cash equivalents and marketable securities $167.0M; Q1 equity offering of 32.89M shares raised net proceeds of $53.6M.
- Casdozokitug Phase 2 1L HCC fully enrolled, first data readout expected mid-2026; tagmokitug combo studies with initial data mid-2026 and 2H 2026.
- Q1 recorded highest new patient starts for LOQTORZI; average treatment duration growing; LOQTORZI remains only FDA-approved treatment for NPC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/0001104659-26-058666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-058666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer